Abbott Laboratories (ABT) Liabilities from Discontinued Operations (2009 - 2016)

Abbott Laboratories has disclosed Liabilities from Discontinued Operations across 5 years of filings, most recently posting $245.0 million for Q4 2016.

• In Q4 2016, Liabilities from Discontinued Operations fell 34.32% year-over-year to $245.0 million; the TTM figure through Dec 2016 stood at $245.0 million (down 34.32% YoY), while the FY2016 annual figure was $245.0 million, down 34.32% from the prior year.
• Liabilities from Discontinued Operations came in at $245.0 million for Q4 2016 at Abbott Laboratories, down from $597.0 million in the prior quarter.
• In the past five years, Liabilities from Discontinued Operations ranged from a high of $721.0 million in Q3 2014 to a low of $169.0 million in Q1 2014.
• Average Liabilities from Discontinued Operations over 4 years is $375.2 million, with a median of $352.2 million recorded in 2013.
• Year-over-year, Liabilities from Discontinued Operations surged 106.89% in 2014 and slumped 50.62% in 2015.
• Over 4 years, Liabilities from Discontinued Operations stood at $386.0 million in 2013, then jumped by 76.17% to $680.0 million in 2014, then slumped by 45.15% to $373.0 million in 2015, then tumbled by 34.32% to $245.0 million in 2016.
• Per Business Quant data, the three most recent Liabilities from Discontinued Operations figures were $245.0 million in Q4 2016, $597.0 million in Q3 2016, and $361.0 million in Q2 2016.